Enlivex Therapeutics Ltd. — FY2020 Form 20-F
Reporting period: Fiscal year ended December 31, 2020. This is an annual report; the supplied filing does not provide standalone fourth-quarter results. Financial statements are prepared under U.S. GAAP and audited. Enlivex is an Israel-based clinical-stage immunotherapy company developing Allocetra, an off-the-shelf cell therapy; it has no approved products or product revenue.
Key financial results and liquidity
| Metric (US$ millions, except per-share data) | 2020 | 2019 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development expense | 6.086 | 5.604 |
| General and administrative expense | 3.699 | 3.015 |
| Operating loss | (9.785) | (8.619) |
| Net loss | (11.824) | (9.384) |
| Basic and diluted loss per share | (0.90) | (1.11) |
| Net cash used in operating activities | (11.007) | (7.041) |
- Gross and operating margins are not meaningful because the company reported no revenue.
- At year-end, cash and cash equivalents were $5.673 million and short-term deposits were $30.034 million; working capital was approximately $33.7 million. Total assets were $40.358 million, total liabilities $4.871 million, and shareholders’ equity $35.487 million.
- Cash used in investing activities was $20.977 million, chiefly reflecting increased short-term deposits and $1.019 million of property and equipment purchases. Financing activities provided $33.082 million, including share issuance and warrant exercises.
- The filing reports no material borrowings. Cash, cash equivalents and restricted cash in the cash-flow statement totaled $7.012 million; this measure excludes short-term deposits.
- Foreign-exchange effects were significant: net financial expense was $2.039 million, primarily from currency movements, while translation gains of $2.277 million were recorded in other comprehensive income.
Changes versus prior year
- Net loss widened by $2.440 million; operating loss increased 14%. R&D expense rose 8.6%, mainly due to higher R&D salaries, while G&A expense increased 23%, including higher director compensation, professional fees and insurance.
- Operating cash outflow increased from $7.041 million to $11.007 million. Financing cash inflow rose to $33.082 million, supporting a year-end increase in cash and deposits.
- Shares outstanding increased from 10,334,126 at December 31, 2019 to 14,587,934 at December 31, 2020, reflecting equity issuance and warrant and option exercises.
Outlook, risks and notable items
- Management expected existing resources, including subsequent financing, to support planned operations through the fourth quarter of 2023. The filing also says the company needs substantial additional capital and that, without it, there is substantial doubt about continuing activities beyond Q4 2023. Funding is not committed and future financing could dilute shareholders or require concessions of rights.
- In February 2021, the company raised approximately $42.1 million net in an underwritten offering, received approximately $5.0 million net from the underwriter’s partial option exercise, and received approximately $6.3 million gross from ATM sales. These are post-year-end events, not FY2020 operating results.
- Allocetra development is concentrated in sepsis, severe or critical COVID-19, and solid tumors. The company initiated a randomized Phase IIb sepsis trial in Q1 2021, planned a COVID-19 Phase IIb or Phase III trial subject to regulatory feedback, and expected to start Phase Ib solid-tumor combination trials in 2021. GvHD development was postponed for the foreseeable future.
- Management described encouraging early clinical findings, including a small sepsis Phase Ib study and combined COVID-19 Phase Ib/II results. These were not confirmatory controlled pivotal results; larger randomized studies and regulatory review remain necessary. Timelines and potential accelerated approval are uncertain.
- Key risks include clinical-trial failure or delay, manufacturing scale-up and contamination, dependence on third parties, regulatory and reimbursement uncertainty, competition, additional financing needs, COVID-19-related disruption, foreign-exchange exposure, and Israeli geopolitical and operating risks.
- IIA grants carry future royalty obligations generally equal to 3%–5% of relevant sales until grants plus interest are repaid. The disclosed contingent obligation was approximately $6.303 million at year-end; transfer or overseas manufacture of supported technology may require IIA approval and additional payments. Operating lease obligations totaled $817,000 undiscounted.
- The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. Management reported effective controls at December 31, 2020; the filing says a material weakness identified for 2018 had been remediated. Stock-based compensation was identified as a critical audit matter.
Important facts for investors to verify
- Review the audited statements and notes for cash availability, short-term deposit restrictions, subsequent financing proceeds, and the basis for the projected runway and going-concern disclosure.
- Track enrollment, interim and top-line results, control-group design, safety findings, and regulatory feedback for the sepsis and COVID-19 trials; verify whether planned trial stages and timelines changed.
- Assess potential dilution from outstanding options and warrants and subsequent share issuances; the filing reported 1,407,683 exercisable warrants outstanding at December 31, 2020.
- Confirm the amount and terms of IIA obligations, including any approvals or added payments triggered by licensing, technology transfer, or manufacturing outside Israel.